{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 44,
        "end": 48
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 108,
        "end": 116
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 173,
        "end": 177
      }
    },
    {
      "id": "T6",
      "obj": "Disease",
      "span": {
        "begin": 198,
        "end": 218
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 227,
        "end": 232
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 122,
        "end": 131
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 108,
        "end": 131
      }
    },
    {
      "id": "T11",
      "obj": "Disease",
      "span": {
        "begin": 44,
        "end": 68
      }
    },
    {
      "id": "T12",
      "obj": "Chemical",
      "span": {
        "begin": 288,
        "end": 292
      }
    },
    {
      "id": "T14",
      "obj": "Disease",
      "span": {
        "begin": 173,
        "end": 218
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "26341921_8",
  "text": "EXPERIMENTAL DESIGN : Using mouse models of EGFR -mutant lung cancer , we tested whether the combination of afatinib plus cetuximab delivered upfront to mice with TKI-na ve EGFR ( L858R ) - induced lung adenocarcinomas delayed tumor relapse and drug-resistance compared with single-agent TKIs ."
}
